The diverse functions of the PD1 inhibitory pathway

AH Sharpe, KE Pauken - Nature Reviews Immunology, 2018 - nature.com
T cell activation is a highly regulated process involving peptide–MHC engagement of the T
cell receptor and positive costimulatory signals. Upon activation, coinhibitory'checkpoints' …

PD-1 and its ligands in tolerance and immunity

ME Keir, MJ Butte, GJ Freeman… - Annu. Rev. Immunol …, 2008 - annualreviews.org
Programmed death 1 (PD-1) and its ligands, PD-L1 and PD-L2, deliver inhibitory signals that
regulate the balance between T cell activation, tolerance, and immunopathology. Immune …

The B7 family revisited

RJ Greenwald, GJ Freeman, AH Sharpe - Annu. Rev. Immunol., 2005 - annualreviews.org
▪ Abstract The discovery of new functions for the original B7 family members, together with
the identification of additional B7 and CD28 family members, have revealed new ways in …

Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial

RW Naumann, A Hollebecque, T Meyer… - Journal of Clinical …, 2019 - ascopubs.org
PURPOSE Nivolumab was assessed in patients with virus-associated tumors in the phase
I/II CheckMate 358 trial (ClinicalTrials. gov identifier: NCT02488759). We report on patients …

The PD1: PD-L1/2 pathway from discovery to clinical implementation

K Bardhan, T Anagnostou, VA Boussiotis - Frontiers in immunology, 2016 - frontiersin.org
The immune system maintains a critically organized network to defend against foreign
particles, while evading self-reactivity simultaneously. T lymphocytes function as effectors …

Advances in graft-versus-host disease biology and therapy

BR Blazar, WJ Murphy, M Abedi - Nature reviews immunology, 2012 - nature.com
Allogeneic haematopoietic stem cell transplantation is used to treat a variety of disorders,
but its efficacy is limited by the occurrence of graft-versus-host disease (GVHD). The past …

Ipilimumab for patients with relapse after allogeneic transplantation

MS Davids, HT Kim, P Bachireddy… - … England Journal of …, 2016 - Mass Medical Soc
Background Loss of donor-mediated immune antitumor activity after allogeneic
hematopoietic stem-cell transplantation (HSCT) permits relapse of hematologic cancers. We …

Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity

L Chen - Nature Reviews Immunology, 2004 - nature.com
Co-signalling molecules are cell-surface glycoproteins that can direct, modulate and fine-
tune T-cell receptor (TCR) signals. On the basis of their functional outcome, co-signalling …

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

C Toffalori, L Zito, V Gambacorta, M Riba, G Oliveira… - Nature medicine, 2019 - nature.com
Transplantation of hematopoietic cells from a healthy individual (allogeneic hematopoietic
cell transplantation (allo-HCT)) demonstrates that adoptive immunotherapy can cure blood …

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

A Goodman, SP Patel, R Kurzrock - Nature reviews Clinical oncology, 2017 - nature.com
Cancer cells can escape T-cell-mediated cellular cytotoxicity by exploiting the inhibitory
programmed cell-death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immune …